Ischämischer und hämorrhagischer Schlaganfall

Henning Schwert; Hansjörg Bäzner

doi:10.1055/a-0592-8603

Der Klinikarzt, Table of Contents

Der Klinikarzt 2018; 47(03): 96-104
DOI: 10.1055/a-0592-8603

Serie

Ischämischer und hämorrhagischer Schlaganfall

Was ist bei der Antikoagulation zu beachten?

Henning Schwert

Neurologische Klinik, Neurozentrum, Klinikum Stuttgart, Stuttgart

,

Hansjörg Bäzner

Neurologische Klinik, Neurozentrum, Klinikum Stuttgart, Stuttgart

› Author Affiliations

Abstract

Zusammenfassung

Schlaganfälle können entweder durch den Verschluss eines hirnversorgenden Gefäßes (ischämischer Schlaganfall) oder durch eine intrazerebrale Blutung (hämorrhagischer Schlaganfall) hervorgerufen werden. Zur Unterscheidung eines hämorrhagischen Schlaganfalls von einem ischämischen Schlaganfall ist eine Bildgebung mittels Computertomografie (CT) oder Magnetresonanztomografie (MRT) erforderlich. Die strikte Trennung von Ischämie und Hämorrhagierisiko wird der klinischen Problematik häufig nicht gerecht, da das gemeinsame Vorliegen von ischämischen (z. B. im Rahmen massiver mikroangiopathischer Läsionslast) und hämorrhagischen Ereignissen (ICBs, zerebrale Mikroblutungen) häufig ist. Eingriffe in die Blutgerinnung sind zur Therapie und Vorbeugung ischämischer Schlaganfälle sinnvoll und geboten, bei hämorrhagischen Ereignissen aber streng kontraindiziert. Daher ist im Vorfeld eine konsequente Abwägung des potentiellen Nutzens gegenüber möglichen Blutungskomplikationen unabdingbar.

Full Text

References

Literatur
1 Kolominsky-Rabas PL, Heuschmann PU, Marschall D. et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 2006; 37: 1179-1183
2 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988
3 Sposato LA, Cipriano LE, Saposnik G. et al. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2015; 14: 377-387
4 Lin HJ, Wolf PA, Kelly-Hayes M. et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27: 1760-1764
5 Diener HC, Weber R, Lip GY, Hohnloser SH. Stroke prevention in atrial fibrillation: do we still need warfarin?. Curr Opin Neurol 2012; 25: 27-35
6 Kamel H, Okin PM, Elkind MS, Iadecola C. et al. Atrial Fibrillation and Mechanisms of Stroke: Time for a New Model. Stroke 2016; 47: 895-900
7 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based ap-proach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272
8 Xian Y, O’Brien EC, Liang L. et al. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA 2017; 317: 1057-1067
9 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962
10 Wilson D, Charidimou A, Shakeshaft C. et al. Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. Neurology 2016; 86: 360-366
11 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18: 1609-1678
12 Whiteley WN, Adams Jr HP, Bath PM. et al. Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurol 2013; 12: 539-545
13 De Caterina R, Husted S, Wallentin L, Andreotti F. et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107
14 Adams Jr HP, Bendixen BH, Kappelle LJ. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41
15 Hart RG, Diener HC, Coutts SB. et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13: 429-438
16 Mohr ¹ JP, Thompson JL, Lazar RM. et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-1451
17 Gladstone DJ, Spring M, Dorian P. et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014; 370: 2467-2477
18 Hylek EM, Go AS, Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026
19 Hemphill 3rd JC, Greenberg SM, Anderson CS. et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2015; 46: 2032-2060
20 Flibotte JJ, Hagan N, O'Donnell J. et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63: 1059-1064
21 Soo YO, Yang SR, Lam WW. et al. Risk vs benefit of anti-thrombotic therapy in ischaemic stroke patients with cerebral microbleeds. J Neurol 2008; 255: 1679-1686
22 Fisher M. MRI screening for chronic anticoagulation in atrial fibrillation. Front Neurol 2013; 4: 137-137
23 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100
24 Fisher M, Vasilevko V, Cribbs DH. Mixed cerebrovascular disease and the future of stroke prevention. Transl Stroke Res 2012; 3 (Suppl. 01) 39-51
25 Kuramatsu JB, Gerner ST, Schellinger PD. et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313: 824-836
26 Biffi A, Kuramatsu JB, Leasure A. et al. Oral Anticoagulation and Functional Outcome after Intracerebral Hemorrhage. Ann Neurol 2017; 82: 755-765
27 Nielsen PB, Larsen TB, Skjøth F. et al. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. Circulation 2015; 132: 517-525
28 Pennlert J, Overholser R, Asplund K. et al. Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation. Stroke 2017; 48: 314-320
29 Phan TG, Koh M, Wijdicks EF. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol 2000; 57: 1710-1713
30 Hawryluk GW, Austin JW, Furlan JC. et al. Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk. J Thromb Haemost 2010; 8: 1500-1508
31 Chandra D, Gupta A, Grover V, Kumar Gupta V. When should you restart anticoagulation in patients who suffer an intracranial bleed who also have a prosthetic valve?. Interact Cardiovasc Thorac Surg 2013; 16: 520-523
32 Aguilar MI, Hart RG, Kase CS. et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007; 82: 82-92
33 Holmes Jr DR, Doshi K S, Kar S. et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol 2015; 65: 2614-2623
34 da Silva IRF, Frontera JA. Resumption of Anticoagulation After Intracranial Hemorrhage. Curr Treat Options Neurol 2017; 19: 39-39